This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Poelman, S. M. Articles by Conzen, S. D. Search for Related Content PubMed PubMed Citation Articles by Poelman, S. M. Articles by Conzen, S. D.

Human Breast Cancer Susceptibility to Paclitaxel Therapy Is Independent of Bcl-2 Expression¹

Departments of Medicine [S. M. P., G. F. F., O. I. O., S. D. C.], Health Studies [M-A. R., T. K.], and Pathology [W. M. R.], University of Chicago, Chicago, Illinois 60637, and LabCorp Inc., Elmhurst, Illinois 60126 [M. O. A.]

In laboratory studies, ectopic overexpression of the antiapoptotic protein Bcl-2 has been shown to result in resistance to the cytotoxic effects of many chemotherapeutic drugs. Furthermore, posttranslational modification of moderately expressed endogenous Bcl-2 has been correlated with susceptibility to paclitaxel treatment in vitro. To determine whether tumor expression of Bcl-2 protein correlates with response and ultimate outcome in vivo, we quantified Bcl-2 expression by immunohistochemical analysis of archived biopsy specimens from metastatic breast cancer patients treated with single-agent paclitaxel. The statistical association between the degree of Bcl-2 expression, objective tumor response, and clinical outcome was then determined. In patients (n = 39) whose tumors had low (10% cells positive) Bcl-2 levels by immunohistochemical analysis, the overall response (complete response + partial response) rate was 21% versus an overall response rate of 22% in patients (n = 36) with high (>10% cells positive) Bcl-2 expression (P = 0.92). In patients with low Bcl-2 expression, the median time to progression was 126 days [95% confidence interval (CI), 63–160 days]. This was not significantly different than the 105 days for patients with high tumor Bcl-2 expression (95% CI, 84–214 days). The median survival time from initiation of paclitaxel therapy for patients with low Bcl-2 expression was 663 days (95% CI, 456-1119 days) and was not significantly different than the 450 days (95% CI, 239-1058 days) observed for patients with high Bcl-2 expression. In conclusion, we found that in metastatic breast cancer, there is no significant association between tumor Bcl-2 expression and response to paclitaxel, median time to progression, or survival, suggesting that the main mechanism of paclitaxel-induced cytotoxicity in breast tumors is independent of Bcl-2 expression.

This article has been cited by other articles:

				A. J. Butt, C. G. Roberts, A. A. Seawright, P. B. Oelrichs, J. K. MacLeod, T. Y.E. Liaw, M. Kavallaris, T. J. Somers-Edgar, G. M. Lehrbach, C. K. Watts, et al. A novel plant toxin, persin, with in vivo activity in the mammary gland, induces Bim-dependent apoptosis in human breast cancer cells. Mol. Cancer Ther., September 1, 2006; 5(9): 2300 - 2309. [Abstract] [Full Text] [PDF]